Kymera Investor Presentation Deck

Scaffolding Proteins ● ● Building Franchises in Immunology and Oncology in Diseases with Large Unmet Needs and Commercial Opportunities ● Scaffolding proteins with clinically validated SMIs Protein degradation affords superior biological and clinical effect Transcription Factors Undrugged transcription factor with strong genetic validation Protein degradation only/best approach to deliver effective drug IRAK4 KT-474 UNDISCLOSED Scaffolding Kinase STAT3 IL4/13 PATHWAY Transcription Factor KYMERA ©2023 KYMERA THERAPEUTICS, INC. NOVEL MOLECULAR GLUE Immunology-Inflammation DERM. GI RHEU. RESPIR. IRAKIMID KT-413 MDM2 KT-253 UNDISCLOSED Scaffolding Kinase STAT3 KT-333 Oncology SOLID TUMORS LEUK. LYMPH. PAGE 6

View entire presentation